



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on May 22, 2002

Michael P. Hayden 48,433  
Name of Attorney or Agent Registration No.  
Michael P. Hayden  
Signature of Attorney or Agent

3761  
L. Pa/K  
105-4-02  
#2/TDS  
P&G Case 8868

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of :  
Joseph R. Diehl et al. : Confirmation No. 7132  
Serial No. 10/078,816 : Group Art Unit 3761  
Filed February 19, 2002 : Examiner  
For Absorbent Article Having A Dehydration Indicator

RECEIVED  
MAY 29 2002  
TECHNOLOGY CENTER R3700

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, record is being made below in a Form PTO/SB08 of documents which the Patent Office may wish to consider in connection with examination of the above-identified patent application. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case. As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 C.F.R. §1.97(h), this Information Disclosure Statement does not constitute an admission of any kind, and specifically is not an admission that the documents listed on attached form PTO/SB08 are, or are considered to be, material to the patentability of the above-identified patent application, as defined in 37 C.F.R. §1.56(b).

1. ☐ 37 C.F.R. §1.97 (b)(1) - U.S. Direct (within 3-months of filing a regular application or converted provisional)

This information disclosure statement, submitted under 37 C.F.R. §1.97 (b)(1), is being filed within three months of the filing date of a national application. Therefore, no fee is believed to be due.

2. ☐ 37 C.F.R. §1.97 (b)(2) - Via PCT (within 3 mo. of Nat'l Stage Entry)

This information disclosure statement, submitted under 37 C.F.R. §1.97 (b)(2), is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application. Therefore, no fee is believed to be due.

3. ☒ 37 C.F.R. §1.97 (b)(3) - (>3 mo. after filing direct or nat'l stage entry, but before 1<sup>st</sup> O.A.)

This information disclosure statement is being submitted under 37 C.F.R. §1.97 (b)(3). Applicants have not received an Office Action on the merits in the present application. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter is enclosed to facilitate charging of the fee, if necessary.

4. ☐ 37 C.F.R. §1.97 (b)(4) - (before the mailing of a first Office Action after the filing of a request for continued examination under §1.114)

This information disclosure statement, submitted under 37 C.F.R. §1.97(b)(4), is being filed with the Request for Continued Examination (RCE) under 37 C.F.R. §1.114.

5. ☐ Information to be Considered with CPA Filing. This information disclosure statement is being filed with a Continued Prosecution Application (CPA) filed under 37 CFR 1.53(d).

6. ☐ 37 C.F.R. §1.97(c) with fee payment - (use after 1<sup>st</sup> Office Action & before Final Office Action or Notice of Allowance)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(c). Applicant(s) have not received a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in the application (e.g., *Ex parte Quayle*) as of the date of this submission. Applicant(s) elect to pay the fee set forth in 37 C.F.R. §1.17(p). Please charge the fee set forth in 37 C.F.R. §1.17(p) to Deposit Account Number 16-2480 in the name of The Procter & Gamble Company. A duplicate copy of this letter is enclosed to facilitate the charging of the fee.

**ADDITIONAL ITEMS TO BE NOTED BY THE EXAMINER:**

☐ (1) Copies of the cited references were previously cited by or submitted to the USPTO in prior application Case No. \_\_\_\_, U.S. Patent Application Serial No. \_\_, filed \_\_. Applicants claim priority to said application under 35 U.S.C. §120. Accordingly, copies of those documents are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d).

OR

☒ (2) Copies of the cited documents are enclosed.

☒ (5) Applicants also respectfully request the Examiner to consider and make of record the copending applications listed on the attached page.



Additional information is attached.

Respectfully submitted,

By Michael P. Hayden  
Michael P. Hayden  
Agent for Applicant(s)  
Registration No. 48,433  
(513) 626-5800

Date: 21 May 2002


Customer No. 27752

(IDS.doc)  
(Last Revised 12/7/01)

## COPENDING APPLICATIONS

<u>Atty. Docket No.</u>	<u>Serial Number</u>	<u>Inventor(s)</u>	<u>Filing Date</u>
7538	09/342,308	Donald C. Roe	June 29, 1998
7538C	09/523,078	Donald C. Roe	March 10, 2000

Please type a plus sign (+) inside this box → [ ]



PTO/SB08A (10-01)

Approved for use through 10/31/2002 OMB 0651-0031  
Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

COMPLETE IF KNOWN

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

SHEET 1 of 2

Application Number	10/078,816
Confirmation Number	7132
Filing Date	February 19, 2002
First Named Inventor	Joseph R. Diehl
Group Art Unit	3761
Examiner Name	
Attorney Docket Number	8868

## U. S. PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. <sup>1</sup>	DOCUMENT NUMBER Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		US-4,287,153	09/01/1981	Towsend	
		US-4,769,215	09/06/1988	Ehrenkranz	
		US-5,141,310	08/25/1992	Boiarski	
		US-5,468,236	11/21/1995	Everhart et al.	
		US-5,500,225	03/19/1996	Laudon et al.	
		US-6,106,461	08/22/2000	Roskin et al.	
		US-6,203,496 B1	03/20/2001	Gael et al.	
		US-6,203,900 B1	03/20/2001	Saika et al.	
		US-6,342,037 B1	01/29/2002	Roe et al.	

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. <sup>1</sup>	FOREIGN PATENT DOCUMENT Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	~	EP 0 342 701 B1	11/23/1989	Franklin Diagnostics, Inc.		
	~	EP 0 524 370 A2	01/27/1993	Miles Inc.		
	~	EP 1 034 758 A1	09/13/2000	Paula Jimenez Cerrato et al.		
	~	JP 10-313,894	12/02/1998	K.K. Daikan		
	~	WO 99/02985 A1	01/21/1999	Lea T. Rosengreen		
	~	WO 99/31486 A1	06/24/1999	Kimberly-Clark Worldwide, Inc.		
	~	WO 00/00148 A1	01/06/2000	Procter & Gamble		
	~	WO 00/00233 A1	01/06/2000	Procter & Gamble		
	~	WO 00/15169 A1	03/23/2000	Paula Jimenez Cerrato		
	~	WO 00/25836 A1	05/11/2000	Procter & Gamble		
	~	WO 00/34781 A2	06/15/2000	Kimberly-Clark Worldwide, Inc.		
	~	WO 00/36416 A1	06/22/2000	Kimberly-Clark Worldwide, Inc.		
	~	WO 00/42958 A1	07/27/2000	3M Innovative Properties Company		
	~	WO 00/57827 A1	10/05/2000	Paul Hartmann AG		
	~	WO 00/65083 A2	11/02/2000	Procter & Gamble		
	~	WO 00/65084 A2	11/02/2000	Procter & Gamble		
	~	WO 00/65096 A1	11/02/2000	Procter & Gamble		
	~	WO 00/65347 A2	11/02/2000	Procter & Gamble		
	~	WO 00/65348 A2	11/02/2000	Procter & Gamble		
	~	WO 00/76558 A1	12/21/2000	SCA Hygiene Products AB		
	~	WO 01/54552 A1	08/02/2001	Procter & Gamble		
	~	WO 01/65263 A2	09/07/2001	Procter & Gamble		



## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS*	Cite No. 14	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	1 <sup>o</sup>
		DENNIS R. EVERHART, Using Self-Assembling Monolayers For Sensors, Chemtech, April 1999, pgs 30-37.	
EXAMINER		DATE CONSIDERED	

RECEIVED  
MAY 29 2002

TECHNOLOGY CENTER R3700

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, D.C. 20231.